Jean-Paul Kress - 05 Dec 2025 Form 4 Insider Report for Vor Biopharma Inc. (VOR)

Role: CEO and Chairman, Director
Signature: Adi Osovsky, Attorney-in-Fact
Issuer symbol: VOR
Transactions as of: 05 Dec 2025
Transactions value $: $0
Form type: 4
Filing time: 09 Dec 2025, 08:00:07 UTC
Previous filing: 27 Jun 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Kress Jean-Paul	CEO and Chairman, Director	C/O VOR BIOPHARMA INC., 500 BOYLSTON STREET, SUITE 1350, BOSTON	Adi Osovsky, Attorney-in-Fact	09 Dec 2025	0001654979

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	VOR	Employee Stock Option (right to buy)	Disposed to Issuer	$0	-4.16M	-100%	$0.00	0	05 Dec 2025	Common Stock	4.16M	$17.80	Direct	F1, F2, F3
transaction	VOR	Employee Stock Option (right to buy)	Award	$0	+4.16M		$0.00	4.16M	05 Dec 2025	Common Stock	4.16M	$8.18	Direct	F2, F3, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On September 18, 2025, the Issuer effected a 1-for-20 reverse stock split. The amounts herein reflect the reverse stock split.
F2	On December 5, 2025, pursuant to the terms of the Issuer's Amended and Restated 2021 Equity Incentive Plan (the "2021 Plan") and 2023 Inducement Plan (the "Inducement Plan"), the Issuer's Board of Directors approved a stock option award repricing, effective as of December 5, 2025 (the "Effective Date"). Except for the new exercise price (see footnote 4 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
F3	1/4th of the shares underlying the option vest on June 26, 2026, with the remainder vesting in equal monthly installments over 3 years, in each case subject to the Reporting Person's continued service as of each such date.
F4	The exercise price of the stock option award is $8.18 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date. Under the terms of the stock option award repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The "Retention Period" commenced on the Effective Date and ends upon the earliest of (i) the date 24 months following the Effective Date; (ii) a Change in Control during the optionholder's Continuous Service (each as defined in the Inducement Plan); and (iii) 30 days prior to the option's original expiration date.